| ORIGINAL ARTICLE |
|
| Year : 2022 | Volume
: 15
| Issue : 4 | Page : 171-178 |
|
|
SARS-CoV-2 infection rates after different vaccination schemes: An online survey in Turkey
Oya Baydar Toprak1, Sennur Ozen2, Berker Ozturk3, Burcu Ozturk4, Ebru Ozturk5, Mehmet Kitapci6, Nurdan Kokturk4
1 Chest Diseases Department, Faculty of Medicine, Cukurova University, Adana, Turkey
2 Department of Pulmonary Medicine, Delta Hospital, Istanbul, Turkey
3 Chest Diseases Department, Aksaray Training and Research Hospital, Aksaray, Turkey
4 Department of Pulmonary Medicine, Faculty of Medicine, Gazi University, Ankara, Turkey
5 Department of Biostatistics, Hacettepe University, Ankara, Turkey
6 Department of Nuclear Medicine, Integra Medical Imaging Center, Ankara, Turkey
Correspondence Address:
Nurdan Kokturk
Department of Pulmonary Medicine, Faculty of Medicine, Gazi University, Ankara
Turkey
 Source of Support: The authors received no extramural funding for the study, Conflict of Interest: None
DOI: 10.4103/1995-7645.340576
|
|
|
Objective: To identify effects of various nationwide vaccination protocols on the evolution of new SARS-CoV-2 infections among adult population and to evaluate the safety of mRNA (BioNTech/ Pfizer) vaccine.
Methods: Totally 10 735 adult volunteers that received at least one dose of BioNTech/Pfizer or triple doses of CoronaVac participated in this cross-sectional-online survey between 1 and 10 September 2021. The information was collected covering a 5-month period from April 2021 to September 2021. Information about people who were vaccinated with only single and double dose CoronaVac were not included in this study.
Results: At least one side effect after single and double dose of BioNTech/Pfizer and triple doses of CoronaVac were observed in 42.1%, 42.5% and 10.9%, respectively. The most common side effects were shoulder/arm pain, weakness/fatigue, muscle/joint pain and headache. The side effects were the most frequent in single BioNTech/Pfizer, while it was the least in triple CoronaVac. The rate of positive PCR tests before vaccination was 17.6%, and decreased to 3.0% after vaccination. The rates of positive SARS CoV-2-PCR were 18.8%, 3.5%, 3.1%, 0.5% and 4.6% in single BioNTech/Pfizer, double BioNTech/Pfizer, double CoronaVac+single BioNTech/Pfizer, double CoronaVac+double BioNTech/Pfizer and triple CoronaVac, respectively. While 1.8% of PCR positive COVID-19 cases needed intensive unit care in the pre-vaccination period, intensive care unit was required in 0%, 1.5%, 2.4%, 0% and 4.2% after single BioNTech/ Pfizer, double BioNTech/Pfizer, double CoronaVac+single BioNTech/ Pfizer, double CoronaVac+double BioNTech/Pfizer and triple CoronaVac, respectively. Reinfection rate after vaccination was 0.4%.
Conclusions: The rarity of COVID-19 infection after vaccination suggests that efficacy of vaccines is maintained. On the other hand, the data underscore the critical importance of continued public health mitigation. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
